How Covid-19 and the rise of digital health has changed regulatory, clinical, and reimbursement dynamics in the medical device industry.
As the life sciences industry works to contain the COVID-19 outbreak, it is clear that the dynamics of the medical device and digital health industries are being disrupted. Going virtual is the new normal and executives of medtech and healthtech businesses, and their investors, need to develop their strategy for navigating their way through the evolving landscape.
In this 45-minute overview delivered by the MCRA All Star team, the panel of experts in their specialties dissected and discussed the ways which the regulatory, clinical and reimbursement pathways change and how you should be planning.
What we will cover:
Glenn Stiegman, MS, Senior Vice President, Clinical and Regulatory Affairs, MCRA
Former FDA Chief of the Orthopedic Devices Branch
Michael John, Vice President, Cardiovascular Regulatory Affairs, MCRA
Former FDA Chief, Interventional Cardiology Devices Branch
Tonya Dowd, MPH, Vice President, Reimbursement, Health Economics & Market Access, MCRA
Iman Ahmad, Director of Clinical Affairs, MCRA
Nikki Batista, Associate Director, Cardiovascular & Digital Health Regulatory Affairs, MCRA
Former FDA Assistant Director of External Heart Rhythm and Rate Device Team for the Division of Cardiac Electrophysiology, Diagnostics, & Monitoring Devices